Table 1 Baseline characteristics of the cohort, including patient’s demographic and clinical characteristics.
From: A decision-making model for prediction of a stable disease course in chronic hepatitis B patients
Stable (n = 64) | Unstable (n = 156) | P-value | |
|---|---|---|---|
Age (years) | 62.99 (± 12.36) | 54.07 (± 13.64) | < 0.001 |
Gender-male N (%) | 30 (46.8%) | 97 (62.1%) | < 0.001 |
Follow up (years) | 4.31 (± 2.15) | 4.5 (± 2.3) | 0.571 |
BMI | 26.41 (± 3.7) | 26.99 (± 5) | 0.418 |
Type 2 DM N (%) | 11 (17.1%) | 31 (19.8%) | 0.162 |
Hypertension N (%) | 21 (32.8%) | 23 (14.7%) | < 0.001 |
Hepatitis D positive N (%) | 1 (1.5%) | 7 (4.4%) | 0.093 |
HBV DNA (IU/ml) | 61.5 [0, 392] | 2552 [344, 23000] | < 0.001 |
AST (U/L) | 24.43 (± 13.28) | 34.41 (± 23.68) | 0.001 |
ALT (U/L) | 20.56 (± 7.63) | 43.3 (± 45.16) | < 0.001 |
ALKP (U/L) | 81.6 (± 38.37) | 74.88 (± 28.29) | 0.164 |
GGT (U/L) | 28.88 (± 28.97) | 37.75 (± 41.47) | 0.16 |
Albumin (gr/dL) | 4.32 (± 0.31) | 4.36 (± 0.45) | 0.544 |
Tot-Bilirubin (mg/dL) | 0.61 (± 0.24) | 0.7 (± 0.32) | 0.064 |
Platelets (K/micl) | 216 (± 62.35) | 217 (± 62.53) | 0.93 |
INR | 1.02 (± 0.38) | 1.03 (± 0.11) | 0.846 |
Fib-4 | 1.4 (± 0.86) | 1.5 (± 1.19) | 0.52 |
FIB-4 > 2.65 N (%) | 5 (7.8%) | 19 (12.1%) | 0.003 |
Alpha-feto protein (ng/ml) | 3.49 (± 2.43) | 3.52 (± 3.25) | 0.954 |
